基于Th17免疫轴调控的双特异性融合蛋白及其在炎症性肠病与银屑病联合治疗中的应用
By designing a bispecific fusion protein IL-23R-TFF3, which combines the functions of IL-23R and TFF3, simultaneous blocking of the IL-23/Th17 inflammatory axis and tissue repair were achieved. This solves the problem that existing drugs cannot simultaneously block inflammation and target the delivery of repair factors, thus improving therapeutic efficacy and safety.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ANKANG CENT HOSPITAL
- Filing Date
- 2026-02-03
- Publication Date
- 2026-07-17
AI Technical Summary
Current medications for treating inflammatory bowel disease and psoriasis cannot simultaneously and effectively block the IL-23/Th17 inflammatory axis and target the delivery of repair factors to the lesion site, resulting in unsatisfactory mucosal healing rates.
A bispecific fusion protein was designed, in which the extracellular ligand binding domain of IL-23R was fused with the full-length sequence of TFF3 via a flexible linker peptide through genetic engineering. IL-23R competitively binds to IL-23 in the lesion site, blocking pro-inflammatory signals, and TFF3 is targeted and delivered to the damaged tissue under the guidance of IL-23R, thereby promoting epithelial migration and barrier remodeling.
It achieves simultaneous anti-inflammatory and repair effects, which is significantly superior to using anti-IL-23 antibodies or TFF3 proteins alone. It improves bioavailability, reduces systemic side effects, and has good drug-like properties and industrialization prospects.
Smart Images
Figure CN121930367B_ABST